Regulatory T cells and tumour immunity - observations in mice and men.
An enormous body of work supports a role for CD4+ CD25+ regulatory cells (Tregs) in shaping the immune response to tumours. Indeed, there is evidence that the cells impede effective tumour immunosurveillance, inhibit vaccine-induced antitumour immune responses and promote tumour progression. Studies exploring the impact of Tregs on tumour development are discussed in the context of manipulating this T-cell population for the purpose of cancer immunotherapy.
Gallimore
Awen
A
Medical Biochemistry and Immunology, Henry Wellcome Building, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK. gallimoream@cf.ac.uk
Godkin
Andrew
A
D000818:Animals; D051858:Forkhead Transcription Factors / Q000097:blood; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D009374:Neoplasms, Experimental / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse